269 related articles for article (PubMed ID: 19309154)
1. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
Nudelman I; Rebibo-Sabbah A; Cherniavsky M; Belakhov V; Hainrichson M; Chen F; Schacht J; Pilch DS; Ben-Yosef T; Baasov T
J Med Chem; 2009 May; 52(9):2836-45. PubMed ID: 19309154
[TBL] [Abstract][Full Text] [Related]
2. Readthrough of dystrophin stop codon mutations induced by aminoglycosides.
Howard MT; Anderson CB; Fass U; Khatri S; Gesteland RF; Atkins JF; Flanigan KM
Ann Neurol; 2004 Mar; 55(3):422-6. PubMed ID: 14991821
[TBL] [Abstract][Full Text] [Related]
3. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.
Nudelman I; Glikin D; Smolkin B; Hainrichson M; Belakhov V; Baasov T
Bioorg Med Chem; 2010 Jun; 18(11):3735-46. PubMed ID: 20409719
[TBL] [Abstract][Full Text] [Related]
4. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
[TBL] [Abstract][Full Text] [Related]
5. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.
Rowe SM; Sloane P; Tang LP; Backer K; Mazur M; Buckley-Lanier J; Nudelman I; Belakhov V; Bebok Z; Schwiebert E; Baasov T; Bedwell DM
J Mol Med (Berl); 2011 Nov; 89(11):1149-61. PubMed ID: 21779978
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations.
Vecsler M; Ben Zeev B; Nudelman I; Anikster Y; Simon AJ; Amariglio N; Rechavi G; Baasov T; Gak E
PLoS One; 2011; 6(6):e20733. PubMed ID: 21695138
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic readthrough strategy for suppression of nonsense mutations in duchenne muscular dystrophy].
Shiozuka M; Matsuda R
Brain Nerve; 2011 Nov; 63(11):1253-60. PubMed ID: 22068478
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
Keeling KM; Bedwell DM
J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
[TBL] [Abstract][Full Text] [Related]
9. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome.
Rebibo-Sabbah A; Nudelman I; Ahmed ZM; Baasov T; Ben-Yosef T
Hum Genet; 2007 Nov; 122(3-4):373-81. PubMed ID: 17653769
[TBL] [Abstract][Full Text] [Related]
10. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
[TBL] [Abstract][Full Text] [Related]
11. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
Kerem E
Curr Opin Pulm Med; 2004 Nov; 10(6):547-52. PubMed ID: 15510065
[TBL] [Abstract][Full Text] [Related]
13. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
[TBL] [Abstract][Full Text] [Related]
14. Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease.
Moosajee M; Gregory-Evans K; Ellis CD; Seabra MC; Gregory-Evans CY
Hum Mol Genet; 2008 Dec; 17(24):3987-4000. PubMed ID: 18809619
[TBL] [Abstract][Full Text] [Related]
15. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.
Baradaran-Heravi A; Niesser J; Balgi AD; Choi K; Zimmerman C; South AP; Anderson HJ; Strynadka NC; Bally MB; Roberge M
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3479-3484. PubMed ID: 28289221
[TBL] [Abstract][Full Text] [Related]
16. Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina.
Goldmann T; Rebibo-Sabbah A; Overlack N; Nudelman I; Belakhov V; Baasov T; Ben-Yosef T; Wolfrum U; Nagel-Wolfrum K
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6671-80. PubMed ID: 20671281
[TBL] [Abstract][Full Text] [Related]
17. In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria.
Ho G; Reichardt J; Christodoulou J
J Inherit Metab Dis; 2013 Nov; 36(6):955-9. PubMed ID: 23532445
[TBL] [Abstract][Full Text] [Related]
18. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
[TBL] [Abstract][Full Text] [Related]
19. Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model.
Du M; Keeling KM; Fan L; Liu X; Bedwell DM
J Biol Chem; 2009 Mar; 284(11):6885-92. PubMed ID: 19136563
[TBL] [Abstract][Full Text] [Related]
20. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.
Ng MY; Li H; Ghelfi MD; Goldman YE; Cooperman BS
Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33414181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
